Friday 20 December 2019

Lupin Receives Approval For Betamethasone Dipropionate Ointment USP

Lupin receives approval for Betamethasone Dipropionate Ointment USP: The company has received approval for its Betamethasone Dipropionate Ointment USP, 0.05%, from the United States Food and Drug Administration, to market a generic equivalent of Diprolene Ointment, 0.05%, of Merck Sharp and Dohme Corp. The product will be manufactured at Lupin’s Pithampur facility, India.

Equity benchmarks are flat as gains in shares of State Bank of India, ICICI Bank and HDFC Bank were offset by losses in shares of HDFC, Kotak Mahindra Bank and ITC.

For more information +91- 6232578593 or visit www.moneymarketmanthan.com

No comments:

Post a Comment

Trends On SGX Nifty Indicate A Positive Opening For The Broader Index In India

Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 31.5 points gain or 0.25 percent. The Nifty future...